Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of safinamide added to a stable single dopamine agonist in early idiopathic Parkinson's disease
2004-000833-12Phase 3Completed
- Sponsor
- Newron Pharmaceuticals
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of safinamide in Parkinson's disease (PD) (3 arms), sponsored by Newron Pharmaceuticals. Primary endpoint: Change in UPDRS Section III total score. Started Nov 2004; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2004-000833-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000833-12.